Global Insulin Glargine Market 2016 Product types, with sales, Revenue, Price,Share and Growth 2021


This report provides detailed analysis of worldwide markets for Insulin Glargine from 2011-2016, and provides extensive market forecasts (2016-2021) by region/country and subsectors. It covers the key technological and market trends in the Insulin Glargine market and further lays out an analysis of the factors influencing the supply/demand for Insulin Glargine, and the opportunities/challenges faced by industry participants. It also acts as an essential tool to companies active across the value chain and to the new entrants by enabling them to capitalize the opportunities and develop business strategies.

Access full report at :

Insulin glargine, marketed under the names Lantus among others, is a long-acting basal insulin analogue, given once daily to help control the blood sugar level of those with diabetes. It consists of microcrystals that slowly release insulin, giving a long duration of action of 18 to 26 hours, with a “peakless” profile (according to the insulin glargine package insert). Pharmacokinetically, it resembles basal insulin secretion of non-diabetic pancreatic beta cells. Sometimes, in type 2 diabetes and in combination with a short acting sulfonylurea (drugs which stimulate the pancreas to make more insulin), it can offer moderate control of serum glucose levels. In the absence of endogenous insulin—type 1 diabetes, depleted type 2 (in some cases) or latent autoimmune diabetes of adults in late stage—insulin glargine needs the support of fast acting insulin taken with food to reduce the effect of prandially derived glucose.

GCC’s report, Global Insulin Glargine Market Outlook 2016-2021, has been prepared based on the synthesis, analysis, and interpretation of information about the global Insulin Glargine market collected from specialized sources. The report covers key technological developments in the recent times and profiles leading players in the market and analyzes their key strategies. The competitive landscape section of the report provides a clear insight into the market share analysis of key industry players. The major players in the global Insulin Glargine market areSanofi (France), Novo Nordisk (Demark), Eli Lilly (USA), Tonghua Dongbao (China), Gan & Lee (China).

Request for sample report at :

The report provides separate comprehensive analytics for the North America, Europe, Asia-Pacific, Middle East and Africa and Rest of World. In this sector, global competitive landscape and supply/demand pattern of Insulin Glargine industry has been provided.


Table of contents

Part 1. Scope of Report

1.1 Research Methodology

1.2 Geographic Scope

1.3 Years Considered

Part 2. Introduction

2.1 Key Findings

2.2 Value Chain Analysis

2.2.2 Upstream

2.2.3 Downstream

Part 3. Manufacture

3.1 Manufacturing Process

3.2 Issues and Trends

Part 4. Cost Structure

4.1 Bill of Materials

4.2 Labor Cost

4.3 Depreciation Cost

4.4 Manufacturing Cost


About Fior Markets

Fior Markets is a leading market intelligence company that sells reports of top publishers in the technology industry. Our extensive research reports cover detailed market assessments that include major technological improvements in the industry. Fior Markets also specializes in analyzing hi-tech systems and current processing systems in its expertise.


Contact Us

Mark Stone

Sales Manager

Phone: (201) 465-4211